Management of adverse events associated with idelalisib treatment: expert panel opinion

Leukemia & Lymphoma
Steven E CoutréAndrew D Zelenetz

Abstract

Idelalisib is a first-in-class selective, oral, phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for the treatment of several types of blood cancer. Idelalisib has demonstrated significant efficacy and a tolerable safety profile in clinical trials. However, the US prescribing information contains a black box warning for fatal and/or severe diarrhea or colitis, hepatotoxicity, pneumonitis and intestinal perforation. An expert panel was convened to review the pathology of these treatment-emergent adverse events (TEAEs) to propose key management tools for patients receiving idelalisib therapy. This article provides an overview of idelalisib TEAEs reported in clinical trials, and a summary of the panel's recommendations for identification and management of idelalisib treatment-emergent diarrhea or colitis as well as a discussion of transaminitis and pneumonitis. For idelalisib-related diarrhea or colitis (including unresolved grade 2 and grade ≥ 3), after exclusion of infectious causes, the panel recommends individualized treatment with budesonide or oral or intravenous steroid therapy.

References

Feb 22, 2002·The Medical Letter on Drugs and Therapeutics
Apr 2, 2003·Nature Reviews. Immunology·Klaus Okkenhaug, Bart Vanhaesebroeck
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Al B BensonScott Wadler
Jul 3, 2007·Cell·Brendan D Manning, Lewis C Cantley
Sep 8, 2009·The American Journal of Cardiology·Chetan V HampoleSanjiv J Shah
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Jan 1, 2012·American Society of Clinical Oncology Educational Book·John C ByrdAmy J Johnson
Aug 19, 2014·Magnetic Resonance Imaging·Jin JinStuart Crozier

❮ Previous
Next ❯

Citations

Jan 29, 2016·Expert Opinion on Pharmacotherapy·Solomon Graf, Ajay Gopal
Apr 5, 2016·Seminars in Oncology·Jennifer R Brown
Dec 15, 2015·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Bart VanhaesebroeckRoberto Piñeiro
Jan 24, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Y CheahM L Wang
Aug 20, 2016·Leukemia Research·Marc SorigueJuan-Manuel Sancho
Aug 27, 2016·Leukemia & Lymphoma·Jorge J CastilloSteven P Treon
Oct 27, 2016·Nature Reviews. Immunology·Carrie L LucasKlaus Okkenhaug
Nov 1, 2016·Expert Review of Hematology·Francesca R MauroRobin Foà
Dec 30, 2016·Nature Reviews. Clinical Oncology·Anas YounesJulie Vose
Jul 1, 2016·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Bernard L MariniAnthony J Perissinotti
Feb 18, 2017·American Journal of Hematology·N Nora BennaniThomas E Witzig
Apr 9, 2017·Annals of Hematology·C ShustikS Coutre
Apr 6, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C S Tam, J F Seymour
Mar 10, 2017·Cancers·David GyoriLen R Stephens
May 19, 2017·Journal of Medicinal Chemistry·Matthew W D PerryLinda Öster
Jan 20, 2017·Nature Reviews. Disease Primers·Thomas J KippsKanti Rai
Sep 26, 2017·Expert Opinion on Investigational Drugs·Pawel Robak, Tadeusz Robak
Sep 26, 2017·Expert Opinion on Investigational Drugs·Benjamin L Lampson, Jennifer R Brown
Apr 8, 2016·Therapeutic Advances in Hematology·Kruti Sheth Nair, Bruce Cheson
May 22, 2018·Expert Opinion on Emerging Drugs·Thomas D Rodgers, Patrick M Reagan
Jul 17, 2018·British Journal of Haematology·Anna H SchuhPeter Hillmen
Jan 23, 2018·Journal of Leukocyte Biology·Saige L Pompura, Margarita Dominguez-Villar
Aug 19, 2018·Pharmacotherapy·Laura A TangTim J Peterson
Oct 10, 2018·Journal of Chemotherapy·Caroline MigaultFirouzé Bani-Sadr
Jan 17, 2019·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Giuseppe Curigliano, Rashmi R Shah
Feb 12, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnPier Luigi Zinzani
Feb 13, 2018·Blood Cancer Journal·Arnon P KaterUNKNOWN HOVON Lunenburg Lymphoma Phase I/II Consortium
Jan 30, 2019·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stalin ChellappaKjetil Taskén
Mar 5, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Bryan DoAmber Rexwinkle
Feb 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David A Fruman
Feb 27, 2016·The European Respiratory Journal·Eglantine HaustraeteAnne Bergeron
Dec 7, 2018·Hematology·Jennifer R Brown

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT01282424
NCT01539512

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Kate Traynor
Journal of the Massachusetts Dental Society
Heather M Abourjaily, Morton Rosenberg
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Angelo CamporealeDouglas K Kelsey
© 2022 Meta ULC. All rights reserved